NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Neuraxis, INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$7.85+0.15 (+1.95%)

Close on Oct 19, 2026

Market cap: $95.14M
P/E (TTM): –
Dividend yield: –

Neuraxis, INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	3.57	2.69	2.46	2.68
Cost of Revenue	0.56	0.36	0.30	0.30
Gross Profit	3.01	2.32	2.16	2.39
Research & Development	0.49	0.43	0.17	0.23
General & Administrative	8.06	7.58	8.33	5.12
Advertising Expenses	0.55	0.23	0.19	0.01
Operating Income	-7.83	-7.16	-6.66	-3.37
Interest Expense	0.07	0.17	0.48	0.32
Other Non-Operating Income	0.03	-1.08	-7.96	-1.41
Gain (Loss) on Sale of Assets	-0.01	–	–	–
Legal Settlements	-0.63	–	–	–
Net Income	-7.80	-8.24	-15	-4.78
Preferred Dividends	0.81	0.21	0	2.19
Net Income to Common	-8.62	-8.45	-15	-5.54
EPS (Basic)(per share)	-0.95	-1.22	-4.50	-2.77
EPS (Diluted)(per share)	-0.95	-1.22	-4.50	-2.77
Shares Outstanding (Basic, Weighted)(shares)	9.08	6.92	3.25	2.00
Shares Outstanding (Diluted, Weighted)(shares)	9.08	6.92	3.25	2.00
EBITDA	-7.77	-7.12	-6.62	-3.34

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 85.6%
Operating margin: -144.5%
Net margin: -144.4%
Return on equity, FY2025: -285.4%

Financial strength

Current ratio: 3.04
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 268.8%

Valuation

P/E ratio: –
Price to sales: 17.90
Price to book: 14.13
Dividend yield: –